Identification of Filamin-A and –B as potential biomarkers for prostate cancer


December 22, 2016

Future Science OA. 2016 Dec 22;3(1):FSO161

Narain NR, Diers AR, Lee A, Lao S, Chan JY, Schofield S, Andreazi J, Ouro-Djobo R, Jimenez JJ, Dalvi A, Wang S, Bunch D, Sun Y, Wu W, Thapa K, Gesta S, Rodrigues LO, Akmaev VR, Vishnudas VK, Sarangarajan R.

Current testing methods for prostate cancer often result in over diagnosis and aggressive interventions in patients with indolent disease. Using Berg’s Interrogative Biology platform, we identified FLNA, FLNB and KRT19 as potential biomarkers of disease from a high confidence, causal, prostate cancer specific network derived from perturbation of prostate cancer cell models. The biomarker panel proteins were validated in a panel of prostate cancer cell lines and found to be secreted from cells, thus demonstrating their potential for detection in noninvasive biofluids. Testing of the biomarker panel in blood samples showed that FLNA and FLNB levels were dysregulated in patients with prostate cancer, but not in patients with benign tumors. These studies highlight the potential use of a panel of biomarkers that includes FLNA and FLNB for detection of prostate cancer.

Learn more: [weblink]

BERG in the News!

BERG is making headlines.  Click here to see the latest breaking news, interviews, and press releases.